Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Incyte Corporation (INCY : NSDQ)
 
 • Company Description   
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Number of Employees: 2,094

 
 • Price / Volume Information   
Yesterday's Closing Price: $74.34 Daily Weekly Monthly
20 Day Moving Average: 1,384,107 shares
Shares Outstanding: 221.51 (millions)
Market Capitalization: $16,466.68 (millions)
Beta: 0.71
52 Week High: $88.26
52 Week Low: $61.91
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.28% 8.94%
12 Week 9.58% 20.48%
Year To Date 1.28% 23.75%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1801 AUGUSTINE CUT-OFF
-
WILMINGTON,DE 19803
USA
ph: 302-498-6700
fax: 302-425-2750
cchiou@incyte.com http://www.incyte.com
 
 • General Corporate Information   
Officers
Herve Hoppenot - Chairman; President; and Chief Executive Officer
Christiana Stamoulis - Chief Financial Officer
Paul Trower - Division VP; Finance
Julian C. Baker - Director
Otis W. Brawley - Director

Peer Information
Incyte Corporation (CORR.)
Incyte Corporation (RSPI)
Incyte Corporation (CGXP)
Incyte Corporation (BGEN)
Incyte Corporation (GTBP)
Incyte Corporation (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45337C102
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 221.51
Most Recent Split Date: 9.00 (2.00:1)
Beta: 0.71
Market Capitalization: $16,466.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.31 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 36.00% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 32.13
Trailing 12 Months: 37.54
PEG Ratio: 0.89
Price Ratios
Price/Book: 4.26
Price/Cash Flow: 31.26
Price / Sales: 5.29
EPS Growth
vs. Year Ago Period: -20.00%
vs. Previous Quarter: 671.43%
Sales Growth
vs. Year Ago Period: 21.25%
vs. Previous Quarter: -15.02%
ROE
03/31/22 - 12.77
12/31/21 - 14.66
09/30/21 - 22.27
ROA
03/31/22 - 9.68
12/31/21 - 11.04
09/30/21 - 16.60
Current Ratio
03/31/22 - 3.71
12/31/21 - 3.65
09/30/21 - 3.94
Quick Ratio
03/31/22 - 3.67
12/31/21 - 3.62
09/30/21 - 3.91
Operating Margin
03/31/22 - 14.06
12/31/21 - 15.44
09/30/21 - 21.84
Net Margin
03/31/22 - 29.95
12/31/21 - 31.76
09/30/21 - 18.35
Pre-Tax Margin
03/31/22 - 18.35
12/31/21 - 19.10
09/30/21 - 21.23
Book Value
03/31/22 - 17.44
12/31/21 - 17.07
09/30/21 - 14.25
Inventory Turnover
03/31/22 - 6.49
12/31/21 - 7.31
09/30/21 - 8.07
Debt-to-Equity
03/31/22 - 0.01
12/31/21 - 0.01
09/30/21 - 0.01
Debt-to-Capital
03/31/22 - 0.81
12/31/21 - 0.83
09/30/21 - 0.99
 

Powered by Zacks Investment Research ©